(-0.04%) 5 476.50 points
(-0.07%) 38 791 points
(-0.01%) 19 920 points
(0.34%) $80.60
(1.22%) $2.82
(0.24%) $2 334.60
(-0.16%) $29.35
(-0.19%) $969.10
(0.01%) $0.932
(-0.16%) $10.64
(0.05%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods...
Stats | |
---|---|
Šios dienos apimtis | 34 503 |
Vidutinė apimtis | 0 |
Rinkos kapitalizacija | 40.09M |
EPS | $-0.0603 ( Q2 | 2024-04-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0780 (6.24%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-26 | Carle Vanessa | Buy | 12 500 | Stock Options |
2023-10-26 | Docherty John Martin | Buy | 30 000 | Stock Options |
2023-10-26 | Bunka Christopher | Buy | 30 000 | Stock Options |
2023-07-25 | Baxter Nicholas W | Buy | 5 000 | Stock Options |
2023-07-25 | Mckechnie William Edward | Buy | 5 000 | Stock Options |
INSIDER POWER |
---|
95.96 |
Last 99 transactions |
Buy: 5 639 011 | Sell: 3 601 735 |
Lexaria Bioscience Corp. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Lexaria Bioscience Corp. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $226 208 |
Bruto pelnas: | $194 708 (86.07 %) |
EPS: | $-1.010 |
FY | 2023 |
Pajamos: | $226 208 |
Bruto pelnas: | $194 708 (86.07 %) |
EPS: | $-1.010 |
FY | 2022 |
Pajamos: | $255 397 |
Bruto pelnas: | $183 556 (71.87 %) |
EPS: | $-1.240 |
FY | 2021 |
Pajamos: | $722 738 |
Bruto pelnas: | $547 392 (75.74 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company\'s DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.